LAUSR

Background and Aim: The real-world study of China PDS with 2083 type 2 diabetes mellitus (T2DM) patients showed that vildagliptin plus metformin (VM) therapy could effectively control the HbA1c with good tolerability. Here, we present the results of baseline BMI subgroups. Materials and Methods:In China PDS, T2DM patients with poor glycemic control on monotherapy were assigned to either VM dual therapy or other oral dual agents(OD) therapy according to local physician’s decision. For this analysis, patients were divided into three subgroups according tobaseline BMI( 28kg/m2). The primary outcome was the proportion of patients with HbA1c Results:In total, 389(149 in VM vs. 240 in OD) patients in BMI 28kg/m2 group were enrolled. Compared with OD, significantly higher proportion patients reached primary outcome in VM in BMI 28kg/m2 group (51.0% vs. 33.9%; P=0.006). Mean HbA1c changes were significantly greater in VM than in OD(BMI 28kg/m2: -1.29% vs. -0.84%; P 28kg/m2 group (4.6% vs. 5.5%, P>0.05). Conclusion:In different baseline BMI groups, vildagliptin plus metformin dual therapy was associated with better glycemic control and was well tolerated compared with OD. Disclosure H. Jin: None. Y. Han: None. L. Chen: None. D. Hu: None. N. Yang: None. X. Shi: None. Q. Li: None. L. Liang: None. L. Zang: None. M. Liu: None. J. He: None. Y. Mu: None.